aibioAgentix Corp. says its June quarter report will be late
Tickers AGTX
Agentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025.
Key facts
- Company
- Agentix Corp. (OTC: AGTX)
- News type
- Distress
- Primary source
- Agentix Corp. NT 10-Q (2025-08-15)
Agentix Corp. has told the Securities and Exchange Commission that it will not file its quarterly report for the fiscal quarter ended June 30, 2025 on time. The notice, on Form 12b-25, is dated August 14, 2025 and is signed by director Rehan Huda.
The company says it has been unable "without unreasonable effort or expense" to compile all the information needed for the financial statements and related disclosures in its Form 10-Q. It expects to file the report on or before August 19, 2025. The form gives a company up to the fifth calendar day after the due date for a quarterly report. Agentix also says it has filed all other periodic reports due over the past 12 months, and it does not expect a significant change in results of operations from the same period a year earlier. The notice gives no reason beyond the need to compile information, and it does not state the company's cash position.
What the company is building
The company's annual report, filed in July 2025, says Agentix has not yet generated or realized meaningful revenues. It was incorporated in Nevada on April 18, 2013 as FairWind Energy, Inc., and changed its name to Agentix Corp. on June 17, 2019. Its earlier business was the design, engineering and manufacture of composite products for the oil and gas industry.
The current business began with a share exchange. On June 1, 2020, the company closed an agreement with GSL Healthcare, Inc. in which it offered and sold 27,932,271 shares of common stock for all of GSL Healthcare's outstanding shares. The former GSL Healthcare shareholders now hold about 88.0% of the issued shares, and GSL Healthcare is a wholly owned subsidiary. In September 2022 the company set up Agentix Australia Pty Ltd to carry out its development work. The annual report says Australia has a tax rebate program that reimburses 43.5% of expenses for biotechnology and pharmaceutical development conducted there.
The company describes itself as a clinical development stage corporation focused on metabolic disease. Its principal objective is two drug candidates designed not to cross the blood-brain barrier. The lead asset, AGTX-2004, also known as DBPR211, is a peripherally acting CB1 receptor antagonist. The annual report says it has shown efficacy in animal models of obesity and type 2 diabetes mellitus, and was well tolerated in animal toxicity models. It says an Investigational New Drug application for AGTX-2004 was cleared by the Food & Drug Administration. The annual report text available does not describe any human study.
The science and the competition
The annual report's own history of this drug class is a warning. It says earlier attempts at peripheral CB1 blockers by Pfizer (otenabant), Merck (taranabant) and Sanofi (rimonabant) were terminated because of toxicities that resulted from those drugs crossing the blood-brain barrier. The company's strategy is to restrict its drugs to the body's periphery, but the animal results it cites are the only efficacy data the annual report describes.
The filing also names competitors. It says Takeda has licensed a monoclonal antibody that targets the peripheral CB1 receptor from Goldfinch Bio, and that Inversago Pharma is developing a peripherally restricted CB1 inverse agonist for Prader-Willi syndrome.
The annual report uses market context to make its case. It cites a 2015 global obesity survey in 195 countries that found 604 million adults and 108 million children were obese. It also cites an International Diabetes Federation estimate that global diabetes prevalence was 8.8% (415 m) in 2015 and is expected to reach 10.4% (642 m) by 2040. Those are the report's own figures, not independently tested by this site.
The business section of the annual report gives no cash balance, debt or going-concern language, so it does not show how long the company can fund its work. A company with no meaningful revenue that cannot file a quarterly report on time gives investors fewer checks on its numbers until the filing arrives. The notice is a late-filing warning, not a finding of misstatement, and the company gives no reason for the delay beyond the time needed to compile its numbers.